Does altering medication to avoid dyskinesia positively alters the breadth of the motor repertoire of patients with Parkinson’s disease? A pilot study
Objective: The aim of this study was to assess the level of drug-induced dyskinesia (DID), the presence of other motor symptoms of PD, and the…The Levodopa Response Trial and the Parkinson Disease Digital Biomarker Challenge: Monitoring symptoms of Parkinson’s disease in the lab and home using wearable sensors
Objective: To leverage a community of researchers and shared wearable data to develop algorithms to estimate the severity of PD specific symptoms. Background: People with…Safinamide add-on therapy increases ON time without dyskinesia in fluctuating Parkinson’s Disease (PD) patients with moderate to severe dyskinesia
Objective: This post-hoc analysis examined safinamide efficacy for providing dyskinesia-free ON time in LID patients. Background: Safinamide has both dopaminergic and glutamate modulating activity. The…Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials
Objective: To assess the impact of dyskinesias in PD on ADLs and the effects of ADS-5102 (amantadine) extended release capsules on these impairments. Background: ADS-5102…Amantadine extended release (Gocovri) reduces dyskinesia and bradykinesia: Evaluation of clinical response with the wearable PKG (Personal Kinetigraph) watch
Objective: To determine the effect of bedtime high-dose amantadine extended release (Gocovri) in 50 consecutive patients experiencing motor fluctuations and dyskinesia. Background: Amantadine extended release…Dyskinesia management in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience
Objective: To elucidate which levodopa-treated COMT-naïve Parkinson’s Disease (PD) patients were at higher risk for developing dyskinesia when starting opicapone (OPC) 50mg or entacapone (ENT).…Final MDS-UPDRS, Part IV Results of the EASE LID 2 Study: Long Term, Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: An objective of this study was to evaluate the long-term duration of ADS-5102 effect on dyskinesia as assessed by the Unified Parkinson’s Disease Rating…Polymorphisms of glutamatergic system genes are associated with levodopa-induced dyskinesia in Parkinson’s disease
Objective: We aimed to study the association between glutamatergic system gene polymorphisms (SLC1A2 – gene, coding excitatory acids transporter, and GRIN2A gene, coding a subunit…The anti-dyskinetic effect of the clinically-available 5-HT3 receptor antagonist granisetron in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of the serotonin 3 (5-HT3) receptor antagonist granisetron, a clinically-available anti-emetic, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Dopamine replacement with L-DOPA…Intraoperative Electromyography can optimize pallidotomy for Parkinson’s disease and dystonias
Objective: The aim of this study is show our experience in use intraoperative electromyography during stereotactic pallidotomy for Parkinson’s disease and dystonia, to help care…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 44
- Next Page »